drugset / Trial / NCT00446784
Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate
Timeline
- Start
- 2007-04
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CE-224,535 | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |